

Manal F Abdelmalek

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4790115/manal-f-abdelmalek-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

13,278
citations

58
h-index

114
g-index

145
ext. papers

17,308
ext. citations

8.1
avg, IF

6.24
L-index

#	Paper	IF	Citations
136	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 385, 956-65	40	1421
135	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
134	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016 , 150, 1147-1159.e5	13.3	629
133	Fructose consumption as a risk factor for non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008 , 48, 993-9	13.4	597
132	Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 1961-71	11.2	479
131	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
130	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018 , 67, 1754-1767	11.2	376
129	Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018 , 68, 1063-1075	13.4	346
128	Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2711-7	0.7	322
127	Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2011 , 55, 666-672	13.4	264
126	NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 391, 1174-1185	40	256
125	Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2013 , 145, 1076-87	13.3	248
124	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. <i>Hepatology</i> , 2019 , 70, 1457-1469	11.2	238
123	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet, The</i> , 2019 , 392, 2705-2717	40	227
122	No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. <i>Gastroenterology</i> , 2014 , 147, 377-84.e1	13.3	212
121	Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2009 , 137, 1478-1488.e8	13.3	204
120	Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014 , 59, 471-82	11.2	188

119	Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011 , 53, 106-15	11.2	182
118	NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2012 , 61, 1323-9	19.2	181
117	High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. <i>Hepatology</i> , 2013 , 58, 1632-43	11.2	177
116	Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014 , 59, 1406-14	11.2	162
115	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018 , 155, 1140-1153	13.3	156
114	Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. <i>Hepatology</i> , 2009 , 50, 1818-26	11.2	151
113	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 156-163.e2	6.9	149
112	Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012 , 55, 1711-21	11.2	143
111	One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2004 , 10, 1240-7	4.5	133
110	Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 51-7	4.5	131
109	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2012 , 55, 419-28	11.2	127
108	Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. <i>Hepatology</i> , 2012 , 56, 952-60	11.2	125
107	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018 , 67, 134-144	11.2	124
106	Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2004 , 10, 199-207	4.5	123
105	Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2001 , 7, 1064-70	4.5	120
104	Nonalcoholic fatty liver disease as a complication of insulin resistance. <i>Medical Clinics of North America</i> , 2007 , 91, 1125-49, ix	7	117
103	Genecriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020 , 72, 892-905	11.2	116
102	Increased production of sonic hedgehog by ballooned hepatocytes. <i>Journal of Pathology</i> , 2011 , 224, 401-10	11.2	113

101	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019 , 70, 1913-1927	11.2	111
100	Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. <i>Liver Transplantation</i> , 2002 , 8, 1000-6	4.5	105
99	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020 , 158, 1334-1345.e5	13.3	105
98	Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. <i>Hepatology</i> , 2003 , 38, 859-68	11.2	104
97	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. <i>Journal of Hepatology</i> , 2019 , 70, 133-141	13.4	101
96	Whipple's arthritis: direct detection of <i>Tropheryma whippelii</i> in synovial fluid and tissue. <i>Arthritis and Rheumatism</i> , 1999 , 42, 812-7		96
95	Nonalcoholic fatty liver disease in women. <i>Women's Health</i> , 2009 , 5, 191-203	3	95
94	Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2015 , 62, 165-75	3.2	93
93	Two cases from the spectrum of nonalcoholic steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 1995 , 20, 127-30	3	92
92	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016 , 64, 85-91	11.2	87
91	Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. <i>Liver International</i> , 2013 , 33, 1062-70	7.9	85
90	Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. <i>American Journal of Transplantation</i> , 2012 , 12, 694-705	8.7	80
89	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018 , 67, 2001-2012	11.2	79
88	A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. <i>American Journal of Transplantation</i> , 2005 , 5, 1111-9	8.7	78
87	Short recovery time after percutaneous liver biopsy: should we change our current practices?. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 926-9	6.9	74
86	Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. <i>European Journal of Nutrition</i> , 2010 , 49, 1-9	5.2	72
85	<i>Tropheryma whippelii</i> DNA is rare in the intestinal mucosa of patients without other evidence of Whipple disease. <i>Annals of Internal Medicine</i> , 2001 , 134, 115-9	8	72
84	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 24-39	24.2	67

83	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. <i>Journal of Hepatology</i> , 2020 , 72, 885-895	13.4	65
82	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. <i>Journal of Pediatrics</i> , 2017 , 187, 141-146.e1	3.6	64
81	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1877-1885.e5	6.9	63
80	Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1162-9	6.9	58
79	Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. <i>Human Pathology</i> , 2012 , 43, 790-800	3.7	55
78	Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. <i>Hepatology</i> , 2015 , 61, 98-107	11.2	51
77	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
76	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020 , 89, 105922	2.3	49
75	Hedgehog pathway and pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013 , 57, 1814-25	11.2	46
74	Association between puberty and features of nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 786-94	6.9	44
73	Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019 , 70, 735-744	13.4	42
72	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020 , 72, 1219-1229	11.2	39
71	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2019 , 156, 88-95.e5	13.3	39
70	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 127-131.e2	6.9	38
69	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1626-1635	0.7	34
68	Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2018 , 2, 1344-1355	6	34
67	Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018 , 155, 1428-1435.e2	13.3	34
66	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. <i>Journal of Hepatology</i> , 2020 , 73, 680-693	13.4	32

65	Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. <i>FASEB Journal</i> , 2013 , 27, 1674-89	0.9	32
64	Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. <i>Liver Transplantation</i> , 2003 , 9, 1253-1257	4.5	32
63	Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2019 , 39, 924-932	7.9	31
62	Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1591-1598	0.7	30
61	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018 , 69, 1365-1370	13.4	29
60	Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. <i>Endocrinology</i> , 2014 , 155, 4591-601	4.8	29
59	Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 754-61	4.5	29
58	Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. <i>Digestive Diseases and Sciences</i> , 1997 , 42, 847-50	4	25
57	Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers. <i>Journal of Pathology</i> , 2016 , 238, 531-42	9.4	25
56	Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. <i>Ultrasound in Medicine and Biology</i> , 2015 , 41, 1948-57	3.5	24
55	Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1333-4	0.7	22
54	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021 , 116, 254-262	0.7	20
53	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020 , 10, 1-21	7.9	20
52	Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine. <i>Gastroenterology</i> , 2021 , 161, 301-317.e16	13.3	18
51	Nonalcoholic fatty liver disease: another leap forward. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 85-86	24.2	18
50	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021 , 161, 1657-1669	13.3	17
49	Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1867-1876.e3	6.9	16
48	Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 1062-9	6.9	16

47	Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. <i>Journal of Clinical Gastroenterology</i> , 1998 , 26, 130-4	3	16
46	Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. <i>Liver International</i> , 2020 , 40, 830-843	7.9	14
45	De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017 , 21, 321-335	4.6	13
44	Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1226-9	4	13
43	Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury. <i>Journal of Clinical Investigation</i> , 2019 , 129, 5278-5293	15.9	13
42	Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2021 , 74, 1220-1233	11.2	12
41	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 274-282	13.4	12
40	PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2019 , 29, 99-113	8.8	11
39	NAFLD: The clinical and economic burden of NAFLD: time to turn the tide. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 685-686	24.2	11
38	IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. <i>Journal of Hepatology</i> , 2013 , 58, 402-3	13.4	11
37	Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient. <i>Transplantation</i> , 2003 , 75, 730-2	1.8	11
36	Rectal bleeding from a mucous fistula secondary to a Dieulafoy's lesion. <i>Journal of Clinical Gastroenterology</i> , 1997 , 24, 259-61	3	10
35	The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Contemporary Clinical Trials</i> , 2021 , 104, 106335	2.3	9
34	Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations. <i>Hepatology</i> , 2021 , 73, 1199-1206	11.2	9
33	Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis. <i>Liver Transplantation</i> , 2006 , 12, 306-9	4.5	8
32	Mechanisms underlying nonalcoholic steatohepatitis. <i>Drug Discovery Today Disease Mechanisms</i> , 2006 , 3, 479-488		8
31	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. <i>Liver Transplantation</i> , 2020 , 26, 68-79	4.5	8
30	A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. <i>Hepatology Communications</i> , 2019 , 3, 1571-1584	6	8

29	Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. <i>PLoS ONE</i> , 2018 , 13, e0204308	3.7	8
28	79-year-old woman with blue toes. <i>Mayo Clinic Proceedings</i> , 1995 , 70, 292-5	6.4	7
27	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021 ,	11.2	7
26	Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. <i>ESC Heart Failure</i> , 2021 , 8, 842-848	3.7	7
25	Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 623-633	13.4	7
24	Exercise Training as Treatment of Nonalcoholic Fatty Liver Disease. <i>Journal of Functional Morphology and Kinesiology</i> , 2017 , 2, 35	2.4	6
23	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021 , 6, 918-932	8.7	6
22	Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3413-3430	4	5
21	Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis. <i>Translational Gastroenterology and Hepatology</i> , 2021 , 6, 13	5.2	5
20	Reply to: The use of acoustic radiation force-based shear stiffness in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012 , 56, 996	13.4	4
19	Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1267-1274.e1	6.9	4
18	Whole-Exome Sequencing Study of Extreme Phenotypes of NAFLD. <i>Hepatology Communications</i> , 2018 , 2, 1021-1029	6	4
17	Nonalcoholic Fatty Liver Disease. <i>North Carolina Medical Journal</i> , 2016 , 77, 216-9	0.6	3
16	Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021 , 5, 608-617	6	3
15	Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	3
14	Reply: Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. <i>Hepatology</i> , 2010 , 51, 1859-1860	11.2	2
13	Acute liver failure occurring immediately following anti-D immune globulin infusion in a patient with chronic hepatitis B infection. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 914-9	4	2
12	The role of bariatric surgery in the management of nonalcoholic steatohepatitis. <i>Current Opinion in Gastroenterology</i> , 2021 , 37, 208-215	3	2

11	Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. <i>Hepatology Communications</i> , 2021 , 5, 598-607	6	2
10	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Hepatology</i> , 2018 , 68, 1646-1648	11.2	1
9	Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH. <i>Clinical Liver Disease</i> , 2021 , 17, 29-32	2.2	1
8	A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. <i>Hepatology</i> , 2021 , 74, 3146-3160	11.2	1
7	Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children.. <i>Epigenetics</i> , 2022 , 1-16	5.7	1
6	Validation of the accuracy of the FAST&score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.. <i>PLoS ONE</i> , 2022 , 17, e0266859	3.7	0
5	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1684	6.9	
4	Reply to Kim et al. <i>American Journal of Gastroenterology</i> , 2017 , 112, 807-808	0.7	
3	Reply: To PMID 24849310. <i>Hepatology</i> , 2015 , 61, 1770-1	11.2	
2	The impact of steatosis and alcohol on hepatitis C. <i>Current Hepatitis Reports</i> , 2007 , 6, 39-45		
1	REPLY. <i>Hepatology</i> , 2021 , 73, 1625	11.2	